Open AccessPredictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib
Author(s) -
Andrea L Inghilesi,
D. Gallori,
Lorenzo Antonuzzo,
Paolo Forte,
Daniela Tomčíková,
Umberto Arena,
Stefano Colagrande,
Silvia Pradella,
B. Fani,
Elena Gianni,
Luca Boni,
Giacomo Laffi,
Francesco Di Costanzo,
Fabio Marra
Publication year - 2014
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v20.i3.786
Subject(s) - sorafenib , hepatocellular carcinoma , medicine , cirrhosis , gastroenterology , liver cancer , adverse effect , stage (stratigraphy) , liver disease , progressive disease , univariate analysis , multivariate analysis , disease , paleontology , biology
To investigate in greater detail the efficacy and safety of sorafenib for the treatment of hepatocellular carcinoma (HCC) in patients with established cirrhosis.